Patent application number | Description | Published |
20140201137 | LOCATION-BASED DATA SYNCHRONIZATION MANAGEMENT - In general, a data synchronization management system is disclosed in which files (and/or other data) are synchronized among two or more client computing devices in connection with a backup of those files. Synchronization polices specify files to be synchronized based on selected criteria including file data, metadata, and location information. In general, files are initially copied from a primary client computing device to secondary storage. Thereafter, files to be synchronized are identified from the secondary storage, and copied to other client computing devices. Additionally, synchronized files may be viewed and accessed through a cloud and/or remote file access interface. | 07-17-2014 |
20140201140 | DATA SYNCHRONIZATION MANAGEMENT - In general, a data synchronization management system is disclosed in which files (and/or other data) are synchronized among two or more client computing devices in connection with a backup of those files. Synchronization polices specify files to be synchronized based on selected criteria including file data, metadata, and location information. In general, files are initially copied from a primary client computing device to secondary storage. Thereafter, files to be synchronized are identified from the secondary storage, and copied to other client computing devices. Additionally, synchronized files may be viewed and accessed through a cloud and/or remote file access interface. | 07-17-2014 |
20140201141 | REQUEST-BASED DATA SYNCHRONIZATION MANAGEMENT - In general, a data synchronization management system is disclosed in which files (and/or other data) are synchronized among two or more client computing devices in connection with a backup of those files. Synchronization polices specify files to be synchronized based on selected criteria including file data, metadata, and location information. In general, files are initially copied from a primary client computing device to secondary storage. Thereafter, files to be synchronized are identified from the secondary storage, and copied to other client computing devices. Additionally, synchronized files may be viewed and accessed through a cloud and/or remote file access interface. | 07-17-2014 |
20140201144 | CRITERIA-BASED DATA SYNCHRONIZATION MANAGEMENT - In general, a data synchronization management system is disclosed in which files (and/or other data) are synchronized among two or more client computing devices in connection with a backup of those files. Synchronization polices specify files to be synchronized based on selected criteria including file data, metadata, and location information. In general, files are initially copied from a primary client computing device to secondary storage. Thereafter, files to be synchronized are identified from the secondary storage, and copied to other client computing devices. Additionally, synchronized files may be viewed and accessed through a cloud and/or remote file access interface. | 07-17-2014 |
20150244775 | WORK FLOW MANAGEMENT FOR AN INFORMATION MANAGEMENT SYSTEM - Disclosed herein are systems and methods for managing information management operations. The system may be configured to employ a work flow queue to reduce network traffic and manage server processing resources. The system may also be configured to forecast or estimate information management operations based on estimations of throughput between computing devices scheduled to execute one or more jobs. The system may also be configured to escalate or automatically reassign notification of system alerts based on the availability of system alert recipients. Various other embodiments are also disclosed herein. | 08-27-2015 |
Patent application number | Description | Published |
20090317488 | Formulations Containing an Ionic Mineral-Ion Exchange Resin Complex and Uses Thereof - A process for preparing a formulation comprising a complex comprising an effective amount of ferrous iron bound to a pharmaceutically acceptable cationic resin and at least one pharmaceutically acceptable carrier is described. Such a formulation may optionally include other desirable dietary supplements including, e.g., vitamins, omega fatty acids, and/or fluoride. The formulation is particularly well adapted for pediatric use, but is also useful for use in adult populations. | 12-24-2009 |
20100087501 | Highly Bioavailable Composition Containing Eprosartan-Poloxamer Complex or 2-(7-Chloro-5-Methyl-4-Oxo-3-Phenyl-4,5-Dihydro-3H-Pyridazine (4,5-b)Indol-1-yl)-N,N-Dimethylacetamide - Poloxamer Complex - A composition including an association complex of a pharmaceutical composition and one or more polyethylene-polypropylene glycol block copolymers (poloxamers) is provided. The pharmaceutical composition may include a member selected from the group consisting of (a) an association complex of an eprosartan composition including eprosartan or a pharmaceutically acceptable salt of eprosartan and (b) the non-zwitterionic compound 2-(7-chloro-5-methyl-4-oxo-3-phenyl-4,S dihydro-3H-pyridazino(4,S-b)indol-1-yl)N,N-dimethylacetamide (NZ). | 04-08-2010 |
20100166858 | MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES - A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described. | 07-01-2010 |
20120015030 | MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES - A solid dose composition containing a mixture of a cured, modified release-barrier coated methylphenidate-ion exchange resin complex-matrix and an uncoated methylphenidate-ion exchange resin complex is described. The barrier coated methylphenidate-ion exchange resin complex-matrix comprises methylphenidate complexed with a pharmaceutically acceptable ion-exchange resin to form the complex which is admixed with a polymer to form a methylphenidate-ion exchange resin complex-matrix, which is subsequently coated with a modified release coating. The modified coating contains polyvinyl acetate polymer and a plasticizer and is cured. | 01-19-2012 |
20120207824 | ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT - An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile. | 08-16-2012 |
20130004452 | Formulations Containing an Ionic Mineral-Ion Exchange Resin Complex and Uses Thereof - A process for preparing a formulation comprising a complex comprising an effective amount of ferrous iron bound to a pharmaceutically acceptable cationic resin and at least one pharmaceutically acceptable carrier is described. Such a formulation may optionally include other desirable dietary supplements including, e.g., vitamins, omega fatty acids, and/or fluoride. The formulation is particularly well adapted for pediatric use, but is also useful for use in adult populations. | 01-03-2013 |
20130004571 | Orally Effective Methylphenidate Extended Release Powder and Aqueous Suspension Product - An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile. | 01-03-2013 |
20130059007 | Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes - A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described. | 03-07-2013 |
20130136797 | Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes - An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making the coated complex and the liquid suspension are described. | 05-30-2013 |
20130261152 | ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT - An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile. | 10-03-2013 |
20140004160 | ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT | 01-02-2014 |
20140030334 | Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes - An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making the coated complex and the liquid suspension are described. | 01-30-2014 |
20140056984 | Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes - An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described. | 02-27-2014 |
20140093578 | NOVEL CLONIDINE FORMULATION - An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile with a single peak, wherein said oral clonidine dosage unit provides a therapeutically effective plasma concentration for at least about 70%, or at least 85% of the twenty-four hour period following the single dose administration. Both liquid and solid formulations are provided, as are methods of treating a patient by a single administration of a formulation of the invention so as to achieve a therapeutic effect for 24-hours. | 04-03-2014 |
20140127306 | Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes - An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described. | 05-08-2014 |
20140212493 | Highly Bioavailable Composition Containing Eprosartan - Poloxamer Complex or 2-(7-Chloro-5-Methyl-4-Oxo-3-Phenyl-4,5-Dihydro-3H-Pyridazine (4,5-b)Indol-1-yl)-N,N-Dimethylacetamide - Poloxamer Complex - A composition including an association complex of a pharmaceutical composition and one or more polyethylene-polypropylene glycol block copolymers (poloxamers) is provided. The pharmaceutical composition may include a member selected from the group consisting of (a) an association complex of an eprosartan composition including eprosartan or a pharmaceutically acceptable salt of eprosartan and (b) the non-zwitterionic compound 2-(7-chloro-S-methyl-4-oxo-3-phenyl-4,S dihydro-3H-pyridazino (4,S-b)indol-1-yl)N, N-dimethylacetamide (NZ). | 07-31-2014 |
20140287038 | Orally Effective Methylphenidate Extended Release Powder and Aqueous Suspension Product - An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile. | 09-25-2014 |
20150024059 | Modified Release Formulations Containing Drug - Ion Exchange Resin Complexes - An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described. | 01-22-2015 |
20150272893 | MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES - A tablet comprising a coated drug-ion exchange resin complex composed of methylphenidate complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated methylphenidate-ion exchange resin complex is provided. The coated methylphenidate-ion exchange resin complex is in admixture with a polymer to form a matrix. Also provided is a tablet comprising a coated drug-ion exchange resin complex composed of dexmethylphenidate complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated dexmethylphenidate-ion exchange resin complex is provided. The coated dexmethylphenidate-ion exchange resin complex is in admixture with a polymer to form a matrix. | 10-01-2015 |
Patent application number | Description | Published |
20090144764 | BILLING ADJUSTMENT SYSTEM FOR MULTIMEDIA CONTENT - A system and method is disclosed for processing refund requests. For IPTV broadcast programs, refund requests initiated by users may be for pay-per-view or on-demand programs. After accepting the refund request, user information and historical event information for the provider network are collected and analyzed using a set of rules. The refund request may be granted or denied, either in whole or in part, based on the user information and the historical event information. In addition, detection of network outages and service interruptions is correlated to the refund requests, whereby remediation service may be initiated for network components determined to be in a fault condition. | 06-04-2009 |
20090216433 | Method and system for managing delivery of content in a navigational environment - We have recognized a limitation that may arise when seeking to deliver both navigational and non-navigational content to a mobile user. The limitation is that the presentation of at least certain non-navigational content may interfere with presentation of the navigational content and vice versa. In accordance with an aspect of this invention, the above mentioned limitation is avoided by the following two steps. The first step is ascertaining an available window of time before a piece of navigational content needs to be presented to the mobile user. The second step is identifying a piece of non-navigational content which can be presented in its totality within the available window of time. Choosing non-navigational content which may be completely presented during an available window of time avoids the limitation noted above. | 08-27-2009 |
20090271261 | Policy driven customer advertising - A system and methodology for providing policy driven, user requested advertising is disclosed. Networked users may be provided with selected advertisements to a targeted network access device during a specified broadcast event based on user preferences. The system includes a computing device coupled to at least one communications network and adapted for: receiving user preferences comprising desired advertising content, and specified network access device information for receiving and displaying the advertising thereon. The user preferences are stored in a database and matched to the user preferences with advertising content by at least one advertiser during the specified broadcast event. The advertisements that meet the user preferences are thereafter communicated over at least one communications network to at least one network access device specified in the user selected preferences. | 10-29-2009 |
20100054136 | APPARATUS AND METHOD FOR MANAGING A NETWORK - A system that incorporates teachings of the present disclosure may include, for example, a server having a controller to receive information from a set top box that is associated with an undesired condition being experienced by a user of the set top box where the information is inputted into the set top box by the user, determine a failure condition associated with the information, perform a first diagnostic process to isolate the failure condition between a network failure and a customer premises equipment (CPE) failure, and transmit correction instructions to the set top box for presentation to the user when the failure condition is isolated to the CPE failure. Other embodiments are disclosed. | 03-04-2010 |
20100063989 | APPARATUS AND METHOD FOR DELIVERING MEDIA CONTENT - A system that incorporates teachings of the present disclosure may include, for example, a mobile communication device, having a controller to capture media content and transmit the media content to a media server with a request for distribution of the media content to one or more targeted recipients according to a user profile associated with the mobile communication device that is stored in the media server, where a format of the media content is adjusted by the media server based at least in part on the user profile. Other embodiments are disclosed. | 03-11-2010 |
20100146567 | APPARATUS AND METHOD FOR DISTRIBUTING MEDIA CONTENT - A system that incorporates teachings of the present disclosure may include, for example, a server having a controller to access multiple media content in response to a request to record the multiple media content from a first communication device, adjust a format of at least a portion of the multiple media content based at least in part on a user profile associated with the first communication device, and compile the adjusted multiple media content for delivery. Other embodiments are disclosed. | 06-10-2010 |
20110141951 | METHODS AND APPARATUS FOR TIMESLOT TELECONFERENCING - Methods and apparatus are provided for a timeslot teleconference. A meeting invite is created for a timeslot teleconference on a computer. Timeslots are created for the timeslot teleconference in the meeting invite on the computer. Participants are designated for the timeslots in the meeting invite on the computer, and the timeslots are different time periods during the timeslot teleconference, which can have variable start and end times, as determined by a host. Reach numbers are added for each of the participants in the meeting invite on the computer, and the reach numbers are contact numbers to call the participants for their respective timeslots. The meeting invite is transmitted to participants on the computer. To participate in the timeslot teleconference, the timeslot teleconference is configured for the reach numbers to be called for the participants to correspond to their respective timeslots and/or the participants to call in for their respective timeslots. | 06-16-2011 |
20130182616 | METHODS AND APPARATUS FOR TIMESLOT TELECONFERENCING - Methods and apparatus are provided for a timeslot teleconference. A meeting invite is created for a timeslot teleconference on a computer. Timeslots are created for the timeslot teleconference in the meeting invite on the computer. Participants are designated for the timeslots in the meeting invite on the computer, and the timeslots are different time periods during the timeslot teleconference, which can have variable start and end times, as determined by a host. Reach numbers are added for each of the participants in the meeting invite on the computer, and the reach numbers are contact numbers to call the participants for their respective timeslots. The meeting invite is transmitted to participants on the computer. To participate in the timeslot teleconference, the timeslot teleconference is configured for the reach numbers to be called for the participants to correspond to their respective timeslots and/or the participants to call in for their respective timeslots. | 07-18-2013 |
Patent application number | Description | Published |
20080213333 | Methods and compositions for fostering and preserving bone growth - A method for augmenting bone in a subject in need thereof including installing within an interior portion of a bone located in the subject a sufficient amount of a biocompatible material to form a scaffold within the bone interior, wherein the scaffold serves as a support for the formation of new bone within the bone interior portion, and administering to the subject a sufficient amount of at least one bone augmentation agent to elevate blood concentration of at least one anabolic agent in the subject. The method may further include administering at least one anti-resorptive agent to the subject in an amount sufficient to substantially prevent resorption of new bone growth. In another embodiment, the method may further include a step of mechanically inducing an increase in osteoblast activity in the subject, wherein the elevation in blood concentration of the anabolic agent and the increase in osteoblast activity at least partially overlap in time. | 09-04-2008 |
20080227134 | Glyoxylate assays and their use of inden tifying natural amidated compounds - Methods for detecting and assaying for glyoxylate, include enzyme-based assays and/or assays for hydrogen peroxide following liberation of hydrogen peroxide from glyoxylate, are disclosed. In some embodiments, the invention is directed to methods for assaying for glyoxylate produced by the reaction of peptidylglycine alpha-amidating monooxygenase (PAM). The subject invention also concerns methods for assaying for the enzyme peptidylglycine alpha-amidating monooxygenase and/or its substrates. The detection of glyoxylate is indicative of the presence of PAM and/or its substrates. The subject invention also concerns methods for screening for peptide hormones, amidated fatty acids, any N-acyl-glycine or N-aryl-glycine conjugated molecule, and generally compounds having a glycine reside in free acid form and attached to a carbonyl group. | 09-18-2008 |
20090023892 | Enzymatic reactions in the presence of keto acids - Conversion in vitro of X-Gly to X-alpha-hydroxy-Gly or X-NH | 01-22-2009 |
20120071410 | CALCITONIN PRODUCTS AND THERAPIES FOR TREATING INFLAMMATORY OR DEGENERATIVE DISEASES - Calcitonin products and therapies for treating inflammatory or degenerative diseases are disclosed herein. The pharmaceutical compositions disclosed herein include a first therapeutic agent that is calcitonin, in free or salt form; a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid; and a pharmaceutically acceptable excipient, carrier or diluent. The methods disclosed herein for treating inflammatory or degenerative diseases in a subject include administering a therapeutically effective amount of calcitonin, in free or salt form, to the subject; and co-administering, as part of a combination therapy, a therapeutically effective amount of a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid to the subject. | 03-22-2012 |
20120142586 | TREATMENT FOR OBESITY - The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like. | 06-07-2012 |
20120149635 | TREATMENT FOR OBESITY - The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like. | 06-14-2012 |
20120183582 | Oral Delivery of Peptides - Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing an active peptide that is amidated at a site that is not naturally amidated. | 07-19-2012 |
20120302497 | METHODS OF TREATING MEDICAL CONDITIONS USING CALCITONIN ANALOGS - The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like. | 11-29-2012 |
20120328666 | ORAL DELIVERY OF PEPTIDE PHARMACEUTICAL COMPOSITIONS - Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide. | 12-27-2012 |
20130034897 | BACTERIAL HOST CELL FOR THE DIRECT EXPRESSION OF PEPTIDES - Expression systems are disclosed for the direct expression of peptide products into the culture media where genetically engineered host cells are grown. High yield was achieved with a special selection of hosts, and/or fermentation processes which include careful control of cell growth rate, and use of an inducer during growth phase. Special universal cloning vectors are provided for the preparation of expression vectors which include control regions having multiple promoters linked operably with coding regions encoding a signal peptide upstream from a coding region encoding the peptide of interest. Multiple transcription cassettes are also used to increase yield. The production of amidated peptides using the expression systems is also disclosed. | 02-07-2013 |
20130072446 | ANTI-INFLAMMATORY PHARMACEUTICAL PRODUCTS - Polypeptides having homology to regions of the N-terminal 50 residues of human Annexin 1 are provided for medical use as anti-inflammatory agents. Some of the polypeptides have homology to the N-terminal 48 residues of human Annexin 1, especially to residues 2-48 and 11-48 thereof. In some embodiments, properties of these compounds are improved by at least one modification at residues corresponding to residues 11, 22, 25 and/or 36 of human Annexin 1, and/or by C-terminal amidation of the polypeptide. Analogs of amino acids 2-26 of human Annexin 1, especially acetylated at the N-terminus and/or amidated at the C-terminus and having modifications at 11 and/or 22 are also disclosed for medical use as anti-inflammatory agents. | 03-21-2013 |
20130183385 | PEPTIDE ANALOGS FOR TREATING DISEASES AND DISORDERS - A peptide having a sequence selected from SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18. Said peptide used for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of apetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test. | 07-18-2013 |
20140073561 | METHODS OF TREATING MEDICAL CONDITIONS USING PEPTIDES - The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like. | 03-13-2014 |
20140249085 | CALCITONIN PRODUCTS AND THERAPIES FOR TREATING INFLAMMATORY OR DEGENERATIVE DISEASES - Calcitonin products and therapies for treating inflammatory or degenerative diseases are disclosed herein. The pharmaceutical compositions disclosed herein include a first therapeutic agent that is calcitonin, in free or salt form; a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid; and a pharmaceutically acceptable excipient, carrier or diluent. The methods disclosed herein for treating inflammatory or degenerative diseases in a subject include administering a therapeutically effective amount of calcitonin, in free or salt form, to the subject; and co-administering, as part of a combination therapy, a therapeutically effective amount of a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid to the subject. | 09-04-2014 |
20150125522 | ORAL DELIVERY OF PEPTIDE PHARMACEUTICAL COMPOSITIONS - Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide. | 05-07-2015 |
20150196617 | Peptide Analogs for Treating Diseases and Disorders - Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. Treatment is effected with a combination therapy of metformin and a peptide with a sequence selected from SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24 administered to a patient. | 07-16-2015 |
Patent application number | Description | Published |
20110306721 | Flame retardant material having enhanced pull through lubricity - A process for preparing fire retardant materials having enhanced lubricity, wherein the process comprises providing a silicone, curable, fire retardant material and partially curing the curable fire retardant material to a semi-fluid, gum-like gel prior to any end use application. | 12-15-2011 |
20130160937 | METHOD OF MANUFACTURING FOOTWEAR USING ADHESIVE FILMS AND COMPOSITE OF ADHESIVE FILMS - Disclosed therein are a method of manufacturing footwear using adhesive films and a composite of the adhesive film, which can allow an outsole and a midsole to be simultaneously molded and formed through the steps of putting the midsole made of EVA foam and the outsole made of rubber into a mold, inserting an adhesive film between the midsole and the outsole, and applying high temperature and high pressure to the midsole and the outsole, thereby not needing to carry out a cleaning process, a primer coating process, and a bonding process when an outsole and a midsole are manufactured, not needing additional facilities for the cleaning and bonding processes, reducing unnecessary manpower, and improving working environments. | 06-27-2013 |
20140039105 | METHOD OF MANUFACTURING FOOTWEAR USING ADHESIVE FILMS AND COMPOSITE OF ADHESIVE FILMS - Disclosed therein are a method of manufacturing footwear using adhesive films and a composite of the adhesive film, which can allow an outsole and a midsole to be simultaneously molded and formed through the steps of putting the midsole made of EVA foam and the outsole made of rubber into a mold, inserting an adhesive film between the midsole and the outsole, and applying high temperature and high pressure to the midsole and the outsole, thereby not needing to carry out a cleaning process, a primer coating process, and a bonding process when an outsole and a midsole are manufactured, not needing additional facilities for the cleaning and bonding processes, reducing unnecessary manpower, and improving working environments. | 02-06-2014 |
20150068060 | COMPOSITE OF ADHESIVE FILMS AND SHOE SOLE USING SAME - Disclosed therein are a method of manufacturing footwear using adhesive films and a composite of the adhesive film, which can allow an outsole and a midsole to be simultaneously molded and formed through the steps of putting the midsole made of EVA foam and the outsole made of rubber into a mold, inserting an adhesive film between the midsole and the outsole, and applying high temperature and high pressure to the midsole and the outsole, thereby not needing to carry out a cleaning process, a primer coating process, and a bonding process when an outsole and a midsole are manufactured, not needing additional facilities for the cleaning and bonding processes, reducing unnecessary manpower, and improving working environments. | 03-12-2015 |